Literature DB >> 10577576

Transthoracic echocardiography using second harmonic imaging: diagnostic alternative to transesophageal echocardiography for the detection of atrial right to left shunt in patients with cerebral embolic events.

H P Kühl1, R Hoffmann, M W Merx, A Franke, C Klötzsch, W Lepper, T Reineke, J Noth, P Hanrath.   

Abstract

OBJECTIVES: We sought to evaluate whether transthoracic contrast echocardiography using second harmonic imaging (SHI) is a diagnostic alternative to transesophageal contrast echocardiography (TEE) for the detection of atrial right to left shunt.
BACKGROUND: Paradoxic embolism is considered to be the major cause of cerebral ischemic events in young patients. Contrast echocardiography using TEE has proven to be superior to transthoracic echocardiography (TTE) for the detection of atrial shunting, SHI is a new imaging modality that enhances the visualization of echocardiographic contrast agents.
METHODS: We evaluated 111 patients with an ischemic cerebral embolic event for the presence of atrial right to left shunt using an intravenous (IV) contrast agent in combination with three different echocardiographic imaging modalities: 1) TTE using fundamental imaging (FI); 2) TTE using SHI; and 3) TEE. The severity of atrial shunting and the duration of contrast visibility within the left heart chambers were evaluated for each imaging modality. Image quality was assessed separately for each modality by semiquantitative scoring (0 = poor to 3 = excellent). Presence of atrial right to left shunt was defined as detection of contrast bubbles in the left atrium within the first three cardiac cycles after contrast appearance in the right atrium either spontaneously or after the Valsalva maneuver.
RESULTS: A total of 57 patients showed evidence of atrial right to left shunt with either imaging modality. Fifty-one studies were positive with TEE, 52 studies were positive with SHI, and 32 were positive with FI (p<0.001 for FI vs. SHI and TEE). The severity of contrast passage was significantly larger using SHI (61.6+/-80.2 bubbles) compared to FI (53.7+/-69.6 bubbles; p<0.005 vs. SHI) but was not different compared to TEE (43.9+/-54.3 bubbles; p = NS vs. SHI). The duration of contrast visibility was significantly longer for SHI (17.4+/-12.4 s) compared to FI (13.1+/-9.7 s; p<0.001) and TEE (11.9+/-9.6 s; p<0.02). Mean image quality improved significantly from FI (1.5+/-0.8) to SHI (2.0+/-0.8; p<0.001 vs. FI) and TEE (2.5+/-0.7; p<0.001 vs. SHI).
CONCLUSIONS: In combination with IV contrast injections, TEE and SHI have a comparable yield for the detection of atrial right to left shunt. Both modalities may miss patients with atrial shunting. In young patients with an unexplained cerebrovascular event and no clinical evidence of cardiac disease, a positive SHI study may obviate the need to perform a TEE study to search for cardiac sources of emboli.

Entities:  

Mesh:

Year:  1999        PMID: 10577576     DOI: 10.1016/s0735-1097(99)00412-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  16 in total

Review 1.  When and how to diagnose patent foramen ovale.

Authors:  F J Pinto
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

2.  Impact of harmonic imaging on transthoracic echocardiographic identification of infective endocarditis and its complications.

Authors:  F Chirillo; A Pedrocco; A De Leo; A Bruni; O Totis; P Meneghetti; P Stritoni
Journal:  Heart       Date:  2005-03       Impact factor: 5.994

3.  Paradoxical embolism in Ebstein's anomaly.

Authors:  C Uyan; M Yazici; A P Uyan; B Dokumaci
Journal:  Exp Clin Cardiol       Date:  2001

4.  Effect of Transmit Beamforming on Clutter Levels in Transthoracic Echocardiography.

Authors:  Vaibhav Kakkad; Melissa LeFevre; Kingshuk Roy Choudhury; Joseph Kisslo; Gregg E Trahey
Journal:  Ultrason Imaging       Date:  2018-04-21       Impact factor: 1.578

Review 5.  Transcranial Doppler ultrasonography: From methodology to major clinical applications.

Authors:  Antonello D'Andrea; Marianna Conte; Massimo Cavallaro; Raffaella Scarafile; Lucia Riegler; Rosangela Cocchia; Enrica Pezzullo; Andreina Carbone; Francesco Natale; Giuseppe Santoro; Pio Caso; Maria Giovanna Russo; Eduardo Bossone; Raffaele Calabrò
Journal:  World J Cardiol       Date:  2016-07-26

6.  Two-dimensional echocardiography using second harmonic imaging for the diagnosis of intracardiac right-to-left shunt: a meta-analysis of prospective studies.

Authors:  Mohammad Khalid Mojadidi; Jared S Winoker; Scott C Roberts; Pavlos Msaouel; Rubine Gevorgyan; Ronald Zolty
Journal:  Int J Cardiovasc Imaging       Date:  2014-04-17       Impact factor: 2.357

7.  Lower patent foramen ovale detection with transthoracic echocardiography in atrial fibrillation.

Authors:  Robert R Attaran; Gary Baweja; Laura Foster; Sam Butman; Vincent L Sorrell
Journal:  Int J Cardiovasc Imaging       Date:  2008-07-01       Impact factor: 2.357

8.  Right-to-left shunt with hypoxemia in pulmonary hypertension.

Authors:  Jean-Frédéric Vodoz; Vincent Cottin; Jean-Charles Glérant; Geneviève Derumeaux; Chahéra Khouatra; Anne-Sophie Blanchet; Bénédicte Mastroïanni; Jean-Yves Bayle; Jean-François Mornex; Jean-François Cordier
Journal:  BMC Cardiovasc Disord       Date:  2009-03-31       Impact factor: 2.298

9.  Transcranial Doppler ultrasonography should it be the first choice for persistent foramen ovale screening?

Authors:  Monika Komar; Maria Olszowska; Tadeusz Przewłocki; Jakub Podolec; Jakub Stępniewski; Bartosz Sobień; Rafał Badacz; Anna Kabłak-Ziembicka; Lidia Tomkiewicz-Pająk; Piotr Podolec
Journal:  Cardiovasc Ultrasound       Date:  2014-05-22       Impact factor: 2.062

10.  Fluoroscopy-Free Pulmonary Vein Isolation in Patients with Atrial Fibrillation and a Patent Foramen Ovale Using Solely an Electroanatomic Mapping System.

Authors:  Michael Kühne; Sven Knecht; Aline Mühl; Tobias Reichlin; Nikola Pavlović; Arnheid Kessel-Schaefer; Beat A Kaufmann; Beat Schaer; Christian Sticherling; Stefan Osswald
Journal:  PLoS One       Date:  2016-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.